Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Correction to Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors.

Taha TY, Aboukhatwa SM, Knopp RC, Ikegaki N, Abdelkarim H, Neerasa J, Lu Y, Neelarapu R, Hanigan TW, Thatcher GRJ, Petukhov PA.

ACS Med Chem Lett. 2019 Aug 2;10(9):1358. doi: 10.1021/acsmedchemlett.9b00336. eCollection 2019 Sep 12.

2.

Replicating and identifying large cell neuroblastoma using high-dose intra-tumoral chemotherapy and automated digital analysis.

Taylor JS, Sha L, Ikegaki N, Zeki J, Deaton R, Harris J, Coburn J, Yavuz B, Sethi A, Shimada H, Kaplan DL, Gann P, Chiu B.

J Pediatr Surg. 2019 Aug 31. pii: S0022-3468(19)30562-7. doi: 10.1016/j.jpedsurg.2019.08.022. [Epub ahead of print]

PMID:
31519361
3.

Silk Reservoirs for Local Delivery of Cisplatin for Neuroblastoma Treatment: In Vitro and In Vivo Evaluations.

Yavuz B, Zeki J, Taylor J, Harrington K, Coburn JM, Ikegaki N, Kaplan DL, Chiu B.

J Pharm Sci. 2019 Aug;108(8):2748-2755. doi: 10.1016/j.xphs.2019.03.019. Epub 2019 Mar 21.

PMID:
30905702
4.

Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.

Taylor JS, Zeki J, Ornell K, Coburn J, Shimada H, Ikegaki N, Chiu B.

J Pediatr Surg. 2019 Jun;54(6):1192-1197. doi: 10.1016/j.jpedsurg.2019.02.028. Epub 2019 Feb 28.

PMID:
30879743
5.

Combined application of Indocyanine green (ICG) and laser lead to targeted tumor cell destruction.

Taylor JS, Zeki J, Ikegaki N, Chen LL, Chiu B.

J Pediatr Surg. 2018 Dec;53(12):2475-2479. doi: 10.1016/j.jpedsurg.2018.08.013. Epub 2018 Sep 4.

PMID:
30244940
6.

Disseminated injection of vincristine-loaded silk gel improves the suppression of neuroblastoma tumor growth.

Zeki J, Taylor JS, Yavuz B, Coburn J, Ikegaki N, Kaplan DL, Chiu B.

Surgery. 2018 Oct;164(4):909-915. doi: 10.1016/j.surg.2018.06.017. Epub 2018 Jul 27.

7.

In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment.

Yavuz B, Zeki J, Coburn JM, Ikegaki N, Levitin D, Kaplan DL, Chiu B.

J Control Release. 2018 Sep 10;285:162-171. doi: 10.1016/j.jconrel.2018.07.002. Epub 2018 Jul 3.

8.

MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group.

Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A, Van Ryn C, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H.

Oncotarget. 2017 Dec 15;9(5):6416-6432. doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19.

9.

Rare MYC-amplified Neuroblastoma With Large Cell Histology.

Matsuno R, Gifford AJ, Fang J, Warren M, Lukeis RE, Trahair T, Sugimoto T, Marachelian A, Asgharzadeh S, Maris JM, Ikegaki N, Shimada H.

Pediatr Dev Pathol. 2018 Sep-Oct;21(5):461-466. doi: 10.1177/1093526617749670. Epub 2018 Feb 9.

PMID:
29426276
10.

Design, Synthesis, and Biological Evaluation of Tetrahydroisoquinoline-Based Histone Deacetylase 8 Selective Inhibitors.

Taha TY, Aboukhatwa SM, Knopp RC, Ikegaki N, Abdelkarim H, Neerasa J, Lu Y, Neelarapu R, Hanigan TW, Thatcher GRJ, Petukhov PA.

ACS Med Chem Lett. 2017 Aug 1;8(8):824-829. doi: 10.1021/acsmedchemlett.7b00126. eCollection 2017 Aug 10. Erratum in: ACS Med Chem Lett. 2019 Aug 02;10(9):1358.

11.

Implantable chemotherapy-loaded silk protein materials for neuroblastoma treatment.

Coburn J, Harris J, Zakharov AD, Poirier J, Ikegaki N, Kajdacsy-Balla A, Pilichowska M, Lyubimov AV, Shimada H, Kaplan DL, Chiu B.

Int J Cancer. 2017 Feb 1;140(3):726-735. doi: 10.1002/ijc.30479. Epub 2016 Nov 3.

12.

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.

Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H.

Br J Cancer. 2015 Jun 30;113(1):57-63. doi: 10.1038/bjc.2015.188. Epub 2015 Jun 2.

13.

Aurora kinase A is a possible target of OSU‑03012 to destabilize MYC family proteins.

Silva A, Wang J, Lomahan S, Tran TA, Grenlin L, Suganami A, Tamura Y, Ikegaki N.

Oncol Rep. 2014 Sep;32(3):901-5. doi: 10.3892/or.2014.3325. Epub 2014 Jul 11.

14.

Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin.

Wang SS, Hsiao R, Limpar MM, Lomahan S, Tran TA, Maloney NJ, Ikegaki N, Tang XX.

Int J Mol Med. 2014 Jan;33(1):35-42. doi: 10.3892/ijmm.2013.1545. Epub 2013 Nov 1.

15.

S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines.

Ikegaki N, Hicks SL, Regan PL, Jacobs J, Jumbo AS, Leonhardt P, Rappaport EF, Tang XX.

Int J Oncol. 2014 Jan;44(1):35-43. doi: 10.3892/ijo.2013.2148. Epub 2013 Oct 25.

16.

Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: a report from the Children's Oncology Group.

Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A, McGrady P, London WB, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H.

Cancer. 2013 Oct 15;119(20):3718-26. doi: 10.1002/cncr.28251. Epub 2013 Jul 30.

17.

Transient treatment with epigenetic modifiers yields stable neuroblastoma stem cells resembling aggressive large-cell neuroblastomas.

Ikegaki N, Shimada H, Fox AM, Regan PL, Jacobs JR, Hicks SL, Rappaport EF, Tang XX.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6097-102. doi: 10.1073/pnas.1118262110. Epub 2013 Mar 11.

18.

Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas.

Torres J, Regan PL, Edo R, Leonhardt P, Jeng EI, Rappaport EF, Ikegaki N, Tang XX.

Int J Oncol. 2010 Oct;37(4):983-91.

19.

Biological significance of EPHA2 expression in neuroblastoma.

Kung B, Zhao H, Hicks SL, Tang XX, Ikegaki N.

Int J Oncol. 2009 Oct;35(4):845-50.

20.

De novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting zinc-finger protein as a new favorable neuroblastoma gene.

Ikegaki N, Gotoh T, Kung B, Riceberg JS, Kim DY, Zhao H, Rappaport EF, Hicks SL, Seeger RC, Tang XX.

Clin Cancer Res. 2007 Oct 15;13(20):6001-9.

21.

The MYCN enigma: significance of MYCN expression in neuroblastoma.

Tang XX, Zhao H, Kung B, Kim DY, Hicks SL, Cohn SL, Cheung NK, Seeger RC, Evans AE, Ikegaki N.

Cancer Res. 2006 Mar 1;66(5):2826-33.

22.

Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma.

Tang XX, Robinson ME, Riceberg JS, Kim DY, Kung B, Titus TB, Hayashi S, Flake AW, Carpentieri D, Ikegaki N.

Clin Cancer Res. 2004 Sep 1;10(17):5837-44.

23.

Effect of 20-epi-1alpha,25-dihydroxyvitamin D3 on the proliferation of human neuroblastoma: role of cell cycle regulators and the Myc-Id2 pathway.

Gumireddy K, Ikegaki N, Phillips PC, Sutton LN, Reddy CD.

Biochem Pharmacol. 2003 Jun 15;65(12):1943-55.

PMID:
12787874
24.

Anti-proliferative effects of 20-epi-vitamin-D3 analogue, KH1060 in human neuroblastoma: induction of RAR-beta and p21(Cip1).

Gumireddy K, Reddy GS, Ikegaki N, Binderup L, Sutton LN, Phillips PC, Reddy CD.

Cancer Lett. 2003 Feb 10;190(1):51-60.

PMID:
12536077
25.

Resistance to chemotherapy mediated by TrkB in neuroblastomas.

Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM.

Cancer Res. 2002 Nov 15;62(22):6462-6.

26.

Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells.

Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM.

Cancer Res. 2002 Mar 15;62(6):1802-8. Erratum in: Cancer Res. 2012 Mar 15;72(6):1588.

27.

Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system.

Eggert A, Grotzer MA, Zuzak TJ, Ikegaki N, Zhao H, Brodeur GM.

Eur J Cancer. 2002 Jan;38(1):92-8.

PMID:
11750845
28.

Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas.

Tang XX, Evans AE, Zhao H, Cnaan A, Brodeur GM, Ikegaki N.

Med Pediatr Oncol. 2001 Jan;36(1):80-2.

PMID:
11464911
29.

Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.

Evans AE, Kisselbach KD, Liu X, Eggert A, Ikegaki N, Camoratto AM, Dionne C, Brodeur GM.

Med Pediatr Oncol. 2001 Jan;36(1):181-4.

PMID:
11464878
30.

TrkA signal transduction pathways in neuroblastoma.

Eggert A, Ikegaki N, Liu XG, Chou TT, Brodeur GM.

Med Pediatr Oncol. 2001 Jan;36(1):108-10.

PMID:
11464858
31.
32.

Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells.

Fan L, Iyer J, Zhu S, Frick KK, Wada RK, Eskenazi AE, Berg PE, Ikegaki N, Kennett RH, Frantz CN.

Cancer Res. 2001 Feb 1;61(3):1073-9.

33.

Expression of the neurotrophin receptor TrkB is associated with unfavorable outcome in Wilms' tumor.

Eggert A, Grotzer MA, Ikegaki N, Zhao H, Cnaan A, Brodeur GM, Evans AE.

J Clin Oncol. 2001 Feb 1;19(3):689-96.

PMID:
11157019
34.

Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma.

Tang XX, Zhao H, Robinson ME, Cnaan A, London W, Cohn SL, Cheung NK, Brodeur GM, Evans AE, Ikegaki N.

Med Pediatr Oncol. 2000 Dec;35(6):656-8.

PMID:
11107140
35.

Different effects of TrkA expression in neuroblastoma cell lines with or without MYCN amplification.

Eggert A, Ho R, Ikegaki N, Liu XG, Brodeur GM.

Med Pediatr Oncol. 2000 Dec;35(6):623-7.

PMID:
11107132
36.

Resistance to TRAIL-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.

Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ikegaki N, Brodeur GM.

Med Pediatr Oncol. 2000 Dec;35(6):603-7.

PMID:
11107127
37.

p75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA.

Eggert A, Sieverts H, Ikegaki N, Brodeur GM.

Med Pediatr Oncol. 2000 Dec;35(6):573-6.

PMID:
11107120
38.

Expression of neurotrophin receptor TrkA inhibits angiogenesis in neuroblastoma.

Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE, Brodeur GM.

Med Pediatr Oncol. 2000 Dec;35(6):569-72.

PMID:
11107119
39.

Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression.

Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM, Phillips PC.

Oncogene. 2000 Sep 21;19(40):4604-10.

40.

Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma.

Eggert A, Ikegaki N, Liu XG, Brodeur GM.

Klin Padiatr. 2000 Jul-Aug;212(4):200-5.

PMID:
10994551
41.

Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma.

Tang XX, Zhao H, Robinson ME, Cohen B, Cnaan A, London W, Cohn SL, Cheung NK, Brodeur GM, Evans AE, Ikegaki N.

Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):10936-41.

42.

High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas.

Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP.

Clin Cancer Res. 2000 May;6(5):1900-8.

43.

Molecular dissection of TrkA signal transduction pathways mediating differentiation in human neuroblastoma cells.

Eggert A, Ikegaki N, Liu X, Chou TT, Lee VM, Trojanowski JQ, Brodeur GM.

Oncogene. 2000 Apr 13;19(16):2043-51.

44.

Relative quantitative RT-PCR protocol for TrkB expression in neuroblastoma using GAPD as an internal control.

Eggert A, Brodeur GM, Ikegaki N.

Biotechniques. 2000 Apr;28(4):681-2, 686, 688-91.

45.

Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts.

Evans AE, Kisselbach KD, Yamashiro DJ, Ikegaki N, Camoratto AM, Dionne CA, Brodeur GM.

Clin Cancer Res. 1999 Nov;5(11):3594-602.

46.

ZPK inhibits PKA induced transcriptional activation by CREB and blocks retinoic acid induced neuronal differentiation.

Reddy UR, Basu A, Bannerman P, Ikegaki N, Reddy CD, Pleasure D.

Oncogene. 1999 Aug 5;18(31):4474-84.

47.

High-level expression of EPHB6, EFNB2, and EFNB3 is associated with low tumor stage and high TrkA expression in human neuroblastomas.

Tang XX, Evans AE, Zhao H, Cnaan A, London W, Cohn SL, Brodeur GM, Ikegaki N.

Clin Cancer Res. 1999 Jun;5(6):1491-6.

48.
49.

MYCN protein expression as a predictor of neuroblastoma prognosis.

Chan HS, Gallie BL, DeBoer G, Haddad G, Ikegaki N, Dimitroulakos J, Yeger H, Ling V.

Clin Cancer Res. 1997 Oct;3(10):1699-706.

Supplemental Content

Loading ...
Support Center